In which clinical settings are there indications to initiate the treatment of type 2 diabetes with a glucagon-like peptide-1 (GLP-1) receptor agonist? With Dr Leszek Czupryniak.
In which clinical settings are there indications to initiate the treatment of type 2 diabetes with SGLT-2 inhibitors? With Dr Leszek Czupryniak.
What are the current pharmacologic treatment options to delay the onset of type 2 diabetes in patients with prediabetes? With Dr Leszek Czupryniak.
What management is recommended in moderate syndrome of inappropriate diuresis? With Dr Ally Prebtani.
How to manage patients with acute signs and symptoms of syndrome of inappropriate diuresis, including rapidly progressing hyponatremia? With Dr Ally Prebtani.
When to suspect and how to diagnose syndrome of inappropriate antidiuresis? With Dr Ally Prebtani.
With the current progress of medicine, can we expect that the use of insulin in people with type 2 diabetes will soon pass into history and the only injection therapy will involve effective drugs from the glucagon-like peptide-1 (GLP-1) receptor agonists, promoting significant weight loss?
What is the place of long-acting insulin analogues with higher than standard concentrations (200 IU/mL and 300 IU/mL) in the treatment of type 2 diabetes? In which patients should we expect the benefits to justify recommending the drug despite the higher cost to the patient?
Which model of insulin therapy is best for patients with type 2 diabetes?
When can we expect a fully autonomic closed-loop system (“artificial pancreas”) to be available for patients? Does it seem possible?
English
Polski
Español
українська